Needham raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $95 from $72 and keeps a Buy rating on the shares after the company announced positive data from its Phase 2 trial of daily oral bivamelagon in Hypothalamic Obesity. The firm increased its PoS for the biva’ program to 70% form 40% based on the results, and lowered its discount rate in its DCF valuation to 8% from 9.5% to account for lower overall risk. With some manageable exceptions biva’ tolerability profile looks better than setmelanotide, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Rhythm Pharmaceuticals price target raised to $95 from $73 at BofA
- Rhythm Pharmaceuticals price target raised to $95 from $80 at Morgan Stanley
- Rhythm Pharmaceuticals price target raised to $123 from $94 at Stifel
- Rhythm Pharmaceuticals price target raised to $129 from $91 at Wells Fargo
- Rhythm Pharmaceuticals: Promising Phase 2 Results and Extended Market Exclusivity Boost Price Target